The White House, FDA, and CDC are evidently not on the same page on COVID-19 booster shots

Pfizer booster shot in France
(Image credit: Thomas Coex/AFP/Getty Images)

The Biden administration has been preparing to roll out COVID-19 booster shots on Sept. 20 for most fully immunized adults, assuming the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) agree. The FDA will weigh the evidence for a Pfizer-BioNTech booster shot at a public meeting on Friday, but internal tensions between the FDA, White House, and CDC are already spilling into the open.

Everyone agrees the level of antibodies from the vaccines wanes over time, but there is disagreement over whether approving a third shot is necessary right now, given the other layers of protection from the vaccines and the mildness of most breakthrough infections. Several countries have already approved booster shots for the general population, and Israel is preparing to offer some people a fourth shot.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.